SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anuh Pharma gains on receiving approval from WHO-Geneva Prequalification

05 Aug 2019 Evaluate

Anuh Pharma is currently trading at Rs. 110.00, up by 0.75 points or 0.69% from its previous closing of Rs. 109.25 on the BSE.

The scrip opened at Rs. 109.00 and has touched a high and low of Rs. 111.40 and Rs. 105.15 respectively. So far 2391 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 5 has touched a 52 week high of Rs. 189.80 on 31-Aug-2018 and a 52 week low of Rs. 101.25 on 02-Aug-2019.

Last one week high and low of the scrip stood at Rs. 125.00 and Rs. 101.25 respectively. The current market cap of the company is Rs. 276.24 crore.

The promoters holding in the company stood at 71.78% while Non-Institutions held 28.22% stake in the company.

Anuh Pharma has received approval from WHO - Geneva Prequalification that the Prequalification Inspection Group has recommended that the API's Pyrimethamine, Pyrazinamide and Sulfadoxine can be considered to be compliant with the standards of Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) published by the World Health Organisation (WHO) for manufacturing and packaging of APIs by chemical synthesis.

Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

Anuh Pharma Share Price

78.40 -0.19 (-0.24%)
25-Jun-2026 11:41 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1878.25
Dr. Reddys Labs. 1352.55
Cipla 1442.60
Zydus Lifesciences 1103.80
Lupin 2376.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: